Annual EBIT
-$100.55 M
+$143.59 M+58.81%
December 31, 2023
Summary
- As of February 7, 2025, MCRB annual earnings before interest & taxes is -$100.55 million, with the most recent change of +$143.59 million (+58.81%) on December 31, 2023.
- During the last 3 years, MCRB annual EBIT has fallen by -$14.35 million (-16.64%).
- MCRB annual EBIT is now -3215.13% below its all-time high of -$3.03 million, reached on December 31, 2012.
Performance
MCRB EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBIT
-$51.03 M
-$21.61 M-73.45%
September 30, 2024
Summary
- As of February 7, 2025, MCRB quarterly earnings before interest & taxes is -$51.03 million, with the most recent change of -$21.61 million (-73.45%) on September 30, 2024.
- Over the past year, MCRB quarterly EBIT has dropped by -$103.43 million (-197.40%).
- MCRB quarterly EBIT is now -174.00% below its all-time high of $68.96 million, reached on September 30, 2021.
Performance
MCRB Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBIT
-$63.53 M
-$10.02 M-18.73%
September 30, 2024
Summary
- As of February 7, 2025, MCRB TTM earnings before interest & taxes is -$63.53 million, with the most recent change of -$10.02 million (-18.73%) on September 30, 2024.
- Over the past year, MCRB TTM EBIT has dropped by -$55.43 million (-683.85%).
- MCRB TTM EBIT is now -347.67% below its all-time high of $25.65 million, reached on March 31, 2024.
Performance
MCRB TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBIT Formula
EBIT = Revenue − COGS − Operating Expenses
MCRB EBIT Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +58.8% | -197.4% | -683.9% |
| 3 y3 years | -16.6% | +23.7% | +74.0% |
| 5 y5 years | -1.6% | +23.7% | +74.0% |
MCRB EBIT Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -60.5% | +58.8% | -197.4% | +26.3% | -347.7% | +75.3% |
| 5 y | 5-year | -60.5% | +58.8% | -174.0% | +26.3% | -347.7% | +75.3% |
| alltime | all time | -3215.1% | +58.8% | -174.0% | +26.3% | -347.7% | +75.3% |
Seres Therapeutics EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$51.03 M(+73.5%) | -$63.53 M(+18.7%) |
| Jun 2024 | - | -$29.42 M(-17.0%) | -$53.51 M(-308.6%) |
| Mar 2024 | - | -$35.47 M(-167.7%) | $25.65 M(-416.5%) |
| Dec 2023 | -$100.55 M(-58.8%) | $52.40 M(-227.8%) | -$8.11 M(-93.6%) |
| Sep 2023 | - | -$41.02 M(-182.5%) | -$127.42 M(-11.9%) |
| Jun 2023 | - | $49.74 M(-171.9%) | -$144.68 M(-43.8%) |
| Mar 2023 | - | -$69.23 M(+3.5%) | -$257.65 M(+5.5%) |
| Dec 2022 | -$244.14 M(+289.6%) | -$66.92 M(+14.8%) | -$244.14 M(+7.8%) |
| Sep 2022 | - | -$58.27 M(-7.8%) | -$226.48 M(+128.2%) |
| Jun 2022 | - | -$63.23 M(+13.5%) | -$99.25 M(+18.7%) |
| Mar 2022 | - | -$55.71 M(+13.1%) | -$83.61 M(+33.4%) |
| Dec 2021 | -$62.67 M(-27.3%) | -$49.26 M(-171.4%) | -$62.67 M(+102.8%) |
| Sep 2021 | - | $68.96 M(-244.9%) | -$30.90 M(-76.1%) |
| Jun 2021 | - | -$47.60 M(+36.9%) | -$129.41 M(+27.1%) |
| Mar 2021 | - | -$34.77 M(+98.8%) | -$101.81 M(+18.1%) |
| Dec 2020 | -$86.20 M(+23.5%) | -$17.49 M(-40.8%) | -$86.20 M(-0.9%) |
| Sep 2020 | - | -$29.55 M(+47.8%) | -$86.99 M(+17.8%) |
| Jun 2020 | - | -$20.00 M(+4.3%) | -$73.84 M(+14.3%) |
| Mar 2020 | - | -$19.16 M(+4.9%) | -$64.61 M(-7.4%) |
| Dec 2019 | -$69.78 M | -$18.28 M(+11.4%) | -$69.78 M(-2.9%) |
| Sep 2019 | - | -$16.41 M(+52.5%) | -$71.83 M(-7.5%) |
| Jun 2019 | - | -$10.76 M(-55.8%) | -$77.63 M(-18.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2019 | - | -$24.33 M(+19.7%) | -$95.01 M(-4.0%) |
| Dec 2018 | -$98.94 M(+10.7%) | -$20.33 M(-8.5%) | -$98.94 M(-7.0%) |
| Sep 2018 | - | -$22.21 M(-21.1%) | -$106.37 M(+16.3%) |
| Jun 2018 | - | -$28.14 M(-0.5%) | -$91.48 M(-0.3%) |
| Mar 2018 | - | -$28.27 M(+1.8%) | -$91.76 M(+2.7%) |
| Dec 2017 | -$89.38 M(-3.7%) | -$27.76 M(+279.5%) | -$89.38 M(+2.4%) |
| Sep 2017 | - | -$7.31 M(-74.3%) | -$87.29 M(-11.9%) |
| Jun 2017 | - | -$28.42 M(+9.8%) | -$99.07 M(+0.3%) |
| Mar 2017 | - | -$25.89 M(+0.8%) | -$98.80 M(+6.4%) |
| Dec 2016 | -$92.84 M(+69.2%) | -$25.67 M(+34.4%) | -$92.82 M(+6.3%) |
| Sep 2016 | - | -$19.09 M(-32.1%) | -$87.30 M(+5.7%) |
| Jun 2016 | - | -$28.14 M(+41.3%) | -$82.60 M(+23.5%) |
| Mar 2016 | - | -$19.92 M(-1.2%) | -$66.87 M(+21.9%) |
| Dec 2015 | -$54.86 M(+232.5%) | -$20.15 M(+40.1%) | -$54.86 M(+26.6%) |
| Sep 2015 | - | -$14.39 M(+16.0%) | -$43.33 M(+33.2%) |
| Jun 2015 | - | -$12.41 M(+57.0%) | -$32.52 M(+43.1%) |
| Mar 2015 | - | -$7.91 M(-8.4%) | -$22.73 M(+37.8%) |
| Dec 2014 | -$16.50 M(+172.3%) | -$8.63 M(+141.2%) | -$16.50 M(+109.7%) |
| Sep 2014 | - | -$3.58 M(+36.7%) | -$7.87 M(+83.4%) |
| Jun 2014 | - | -$2.62 M(+56.6%) | -$4.29 M(+156.6%) |
| Mar 2014 | - | -$1.67 M | -$1.67 M |
| Dec 2013 | -$6.06 M(+99.8%) | - | - |
| Dec 2012 | -$3.03 M | - | - |
FAQ
- What is Seres Therapeutics annual earnings before interest & taxes?
- What is the all time high annual EBIT for Seres Therapeutics?
- What is Seres Therapeutics annual EBIT year-on-year change?
- What is Seres Therapeutics quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Seres Therapeutics?
- What is Seres Therapeutics quarterly EBIT year-on-year change?
- What is Seres Therapeutics TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Seres Therapeutics?
- What is Seres Therapeutics TTM EBIT year-on-year change?
What is Seres Therapeutics annual earnings before interest & taxes?
The current annual EBIT of MCRB is -$100.55 M
What is the all time high annual EBIT for Seres Therapeutics?
Seres Therapeutics all-time high annual earnings before interest & taxes is -$3.03 M
What is Seres Therapeutics annual EBIT year-on-year change?
Over the past year, MCRB annual earnings before interest & taxes has changed by +$143.59 M (+58.81%)
What is Seres Therapeutics quarterly earnings before interest & taxes?
The current quarterly EBIT of MCRB is -$51.03 M
What is the all time high quarterly EBIT for Seres Therapeutics?
Seres Therapeutics all-time high quarterly earnings before interest & taxes is $68.96 M
What is Seres Therapeutics quarterly EBIT year-on-year change?
Over the past year, MCRB quarterly earnings before interest & taxes has changed by -$103.43 M (-197.40%)
What is Seres Therapeutics TTM earnings before interest & taxes?
The current TTM EBIT of MCRB is -$63.53 M
What is the all time high TTM EBIT for Seres Therapeutics?
Seres Therapeutics all-time high TTM earnings before interest & taxes is $25.65 M
What is Seres Therapeutics TTM EBIT year-on-year change?
Over the past year, MCRB TTM earnings before interest & taxes has changed by -$55.43 M (-683.85%)